A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 1, 2006, Pages 217-222

  Shikama, Naoto ^a   Oguchi, Masahiko ^b   Isobe, Koichi ^c   Nakamura, Katsumasa ^d   Tamaki, Yoshio ^e   Hasegawa, Masatoshi ^f   Kodaira, Takeshi ^g   Sasaki, Shigeru ^a   Kagami, Yoshikazu ^h  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e GUNMA PREFECTURAL CANCER CENTER   (Japan)

^f NARA MEDICAL UNIVERSITY   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h NATIONAL CANCER CENTER   (Japan)

Author keywords

Aggressive lymphoma; Chemotherapy; Dose intensity; Elderly patients; Radiotherapy

Indexed keywords

CHEMOTHERAPY; DISEASES; NETWORK PROTOCOLS; PATIENT MONITORING; RADIATION; TOXICITY;

AGGRESSIVE LYMPHOMA; DOSE-INTENSITY; ELDERLY PATIENTS; RITUXIMAB;

RADIOTHERAPY;

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEOPLASM; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PREDNISOLONE; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; SURVIVAL RATE; VINCRISTINE;

EID: 33746809042     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.04.006     Document Type: Article

References (27)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
2. Kouroukis C.T., Browman G.P., Esmail R., and Meyer R.M. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma. A systematic review. Ann Intern Med 136 (2002) 144-152
3. Campbell C., Sawka C., Franssen E., and Berinstein N.L. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support. Leuk Lymphoma 35 (1999) 119-127
4. Gomez H., Hidalgo M., Casanova L., et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma. Results of a multivariate analysis. J Clin Oncol 16 (1998) 2065-2069
5. Dixon D.O., Neilan B., Jones S.E., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. The Southwest Oncology Group experience. J Clin Oncol 4 (1986) 295-305
6. Lee K.W., Kim D.Y., Yun T., et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients. Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 98 (2003) 2651-2656
7. Tirelli U., Zagonel V., Serraino D., et al. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older. A retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study. J Clin Oncol 6 (1988) 1708-1713
8. Balducci L., and Lyman G.H. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 19 (2001) 1583-1585
9. Lyman G.H., Dale D.C., Friedberg J., et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma. A nationwide study. J Clin Oncol 22 (2004) 4302-4311
10. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21-26
11. Miller T.P. The limits of limited stage lymphoma. J Clin Oncol 22 (2004) 2982-2984
12. Shenkier T.N., Voss N., Fairey R., et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma. An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20 (2002) 197-204
13. Harris N.L., Jaffe E.S., Diebold J., et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10 (1999) 1419-1432
14. Cheson B.D., Horning S.J., Coiffier B., et al., NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17 (1999) 1244-1253
15. Oguchi M., Izuno I., Takei K., et al. Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly. Usefulness of local and regional irradiation and reduced dose chemotherapy. Int J Radiat Oncol Biol Phys 37 (1997) 87-92
16. Epelbaum R., Haim N., Leviov M., et al. Full dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma. Acta Oncol 34 (1995) 87-91
17. Doorduijn J.K., van der Holt B., van Imhoff G.W., et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 3041-3050
18. Tirelli U., Errante D., Van Glabbeke M., et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma. Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16 (1998) 27-34
19. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma. A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
20. Pfreundschuh M., Trumper L., Ma D., et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab. Early stopping after the first interim analysis. [Abstract]. Pro Am Soc Clin Oncol 23 (2004) 556
21. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas. Results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 634-641
22. Epelbaum R., Haim N., Ben-Shahar M., et al. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24 (1988) 533-538
23. Kwak L.W., Halpern J., Olshen R.A., and Horning S.J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma. Results of a tree-structured survival analysis. J Clin Oncol 8 (1990) 963-977
24. Horning S.J., Weller E., Kim K., et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma. Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22 (2004) 3032-3038
25. Fillet G., Bonnet N., and Mounier N. Radiotherapy is unnecessary in elderly patients with localized aggressive non Hodgkin's lymphoma. Results of the GELA LHN 93-4 study. Proc Am Soc Hematol 100 (2002) 92a [Abstract]
26. Fisher R.I., Miller T.P., and O'Connor O.A. Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program) (2004) 221-236
27. Miller T.P., Unger J.M., and Spier C.M. Effect of adding rituximab to three cycles of CHOP plus involved field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood 104 (2004) 48a [Abstract]